CytomX Therapeutics (CTMX) Competitors $2.13 +0.09 (+4.41%) Closing price 04:00 PM EasternExtended Trading$2.11 -0.02 (-0.94%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. AVBP, TRVI, PHAR, DAWN, DNTH, IOVA, EOLS, ABUS, AKBA, and ZYBTShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Evolus (EOLS), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Iovance Biotherapeutics Evolus Arbutus Biopharma Akebia Therapeutics Zhengye Biotechnology ArriVent BioPharma (NASDAQ:AVBP) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Do analysts rate AVBP or CTMX? ArriVent BioPharma currently has a consensus price target of $39.29, indicating a potential upside of 90.43%. CytomX Therapeutics has a consensus price target of $5.33, indicating a potential upside of 150.39%. Given CytomX Therapeutics' higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, AVBP or CTMX? ArriVent BioPharma has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Is AVBP or CTMX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to ArriVent BioPharma's net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% CytomX Therapeutics 10.96%-41.47%8.11% Does the media prefer AVBP or CTMX? In the previous week, CytomX Therapeutics had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 17 mentions for CytomX Therapeutics and 14 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.54 beat CytomX Therapeutics' score of 0.36 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, AVBP or CTMX? CytomX Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$3.77-5.47CytomX Therapeutics$147.56M1.16-$570K$0.484.44 Do insiders and institutionals have more ownership in AVBP or CTMX? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer AVBP or CTMX? CytomX Therapeutics received 356 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 95.83% of users gave ArriVent BioPharma an outperform vote while only 65.46% of users gave CytomX Therapeutics an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes2395.83% Underperform Votes14.17%CytomX TherapeuticsOutperform Votes37965.46% Underperform Votes20034.54% SummaryCytomX Therapeutics beats ArriVent BioPharma on 12 of the 18 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$171.72M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio12.539.0626.7119.71Price / Sales1.16251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book-3.006.456.774.50Net Income-$570,000.00$143.98M$3.23B$248.22M7 Day Performance6.50%2.41%1.80%0.56%1 Month Performance189.36%4.56%11.10%13.17%1 Year Performance13.30%-2.67%17.11%7.30% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.2271 of 5 stars$2.13+4.4%$5.33+150.4%+9.1%$164.47M$147.56M12.53170Analyst RevisionAVBPArriVent BioPharma1.0187 of 5 stars$19.99-0.8%$39.00+95.1%+2.6%$680.56MN/A-7.7840Analyst ForecastTRVITrevi Therapeutics3.5963 of 5 stars$6.70+1.5%$17.56+162.1%+126.4%$669.28MN/A-15.2320News CoveragePositive NewsAnalyst ForecastPHARPharming Group1.7842 of 5 stars$9.81-2.2%$30.00+206.0%+11.2%$667.04M$297.20M-37.71280Gap DownDAWNDay One Biopharmaceuticals2.7495 of 5 stars$6.58+2.0%$30.57+364.6%-57.5%$666.96M$161.92M-6.3960DNTHDianthus Therapeutics1.2799 of 5 stars$20.08+2.5%$54.33+170.6%-23.7%$645.09M$6.24M-8.0380IOVAIovance Biotherapeutics4.4338 of 5 stars$1.93+10.3%$14.80+666.8%-83.0%$644.49M$212.68M-1.30500Trending NewsHigh Trading VolumeEOLSEvolus3.611 of 5 stars$9.98+1.8%$23.75+138.0%-27.1%$643.42M$266.27M-10.97170Gap UpHigh Trading VolumeABUSArbutus Biopharma2.0539 of 5 stars$3.35+3.7%$5.50+64.2%-1.2%$641.46M$6.17M-7.7990News CoverageGap UpAKBAAkebia Therapeutics4.2848 of 5 stars$2.43-4.7%$6.63+172.6%+148.7%$636.14M$160.18M-10.56430High Trading VolumeZYBTZhengye BiotechnologyN/A$13.43+30.3%N/AN/A$633.44M$189.75M0.00278 Related Companies and Tools Related Companies ArriVent BioPharma Competitors Trevi Therapeutics Competitors Pharming Group Competitors Day One Biopharmaceuticals Competitors Dianthus Therapeutics Competitors Iovance Biotherapeutics Competitors Evolus Competitors Arbutus Biopharma Competitors Akebia Therapeutics Competitors Zhengye Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTMX Stock Free CTMX Stock Alerts